Bioventus (BVS)
(Delayed Data from NSDQ)
$5.20 USD
+0.04 (0.78%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $5.19 -0.01 (-0.19%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.20 USD
+0.04 (0.78%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $5.19 -0.01 (-0.19%) 7:58 PM ET
4-Sell of 5 4
B Value A Growth C Momentum A VGM
Zacks News
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -182.76% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.
3 Value Medical Stocks to Buy for Safety Amid Market Volatility
by Indrajit Bandyopadhyay
We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -30.77% and 3.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 5th
by Zacks Equity Research
BVS, BFAM and ESTE have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2023.
Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
ProPhase Labs, Inc. (PRPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -500% and 6.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are Options Traders Betting on a Big Move in Bioventus (BVS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Bioventus (BVS) stock based on the movements in the options market lately.
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Jazz Pharmaceuticals (JAZZ) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Jazz (JAZZ) delivered earnings and revenue surprises of -113.73% and 0.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Xencor (XNCR) delivered earnings and revenue surprises of 75.90% and 8.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aerie (AERI) delivered earnings and revenue surprises of 38.46% and 2.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Bioventus (BVS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Bioventus (BVS) stock based on the movements in the options market lately.
Company News for Mar 11, 2022
by Zacks Equity Research
Companies in The News Are: CLVT,BVS,KRO,CRWD
ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
ChemoCentryx (CCXI) delivered earnings and revenue surprises of -1.75% and 33.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study
by Zacks Equity Research
PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.
3 Small Biotech Stocks in Focus on World Arthritis Day
by Indrajit Bandyopadhyay
Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.
Concert (CNCE) Initiates Second Phase III Hair Loss Study
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) is developing its lead pipeline candidate, CTP-543, for treating alopecia areata. Two late-stage studies are evaluating the candidate in AA patients to support a potential NDA filing.
Will Bioventus (BVS) Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Bioventus (BVS).